Floatz logo

ZOLPIDEM

Major Depressive Disorder

Sultan Qaboos UniversitySmall moleculePhase 4 / ApprovedActive
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

234 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Zelapar
Corium Innovations, Inc.
Phase 4BBB
Risperdal
Johns Hopkins University
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Vortioxetine
Mayo Clinic
Phase 4BBB
Opc-34712
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

ZOLPIDEM is also rated in:

insomniaDormant
BB
Indicative ·
70 / 100
View asset →
sleep disorder, initiating and maintaining sleepDormant
BB
Indicative ·
65 / 100
View asset →
sleep disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →